Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELEB: RGN-137 for EB
NCT03578029Phase 2Terminated
- Sponsor
- Lenus Therapeutics, LLC
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in junctional epidermolysis bullosa (JEB) and dystrophic epidermolysis bullosa (DEB) comparing RGN-137 with Placebo (2 arms). Primary endpoint: Time to achieving 50% reduction in area of each index wound. Started May 2019; status: terminated.
02
Drugs
GT-211
03
Conditions
junctional epidermolysis bullosa (JEB)dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT03578029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03578029.